Cantor Fitzgerald raised its price target on Strongbridge Biopharma (NASDAQ: SBBP) to $17.00 (from $14.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Analyst PT Change Hot Comments Momentum Movers

Strongbridge Biopharma (SBBP) 10% Owner Buys ~361K SharesAugust 9, 2018 12:36 PM Strongbridge Biopharma (SBBP) climbs 42% after announcing results from Phase 3 study evaluating RECORLEV for treatment of endogenous Cushing’s syndromeAugust 8, 2018 6:45 AM Strongbridge Biopharma (SBBP) Reports Positive Top-Line Results from Pivotal Phase 3 SONICS Study of RECORLEV (levoketoconazole)August 8, 2018 6:40 AM